glp-1 agonist drug interactions Table 5 from Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Class Review Advances in GLP-1 receptor agonists:

This underscores the need to investigate non-metabolic mechanisms contributing to their efficacy, particularly their ability to modulate inflammation, a key driver of many chronic diseases in which these therapies show benefit

Peak VO 2 improvement was not supported by the pharmacokinetic/pharmacodynamic modelling, indicating no relationship between exposure to albiglutide and peak VO 2

JAMA Health Forum

Indeed, our correlation analysis which suggests that greater weight loss is associated with greater pelvis BMD loss do align with prior work (Zibellini et al., 2015) and support future research to evaluate the effect of GLP1Ra use on skeletal health outcomes, particularly with GLP1Ra-based therapies capable of producing greater weight loss in older adults

GLP #2 has also demonstrated success over the long term

That changed when the SURMOUNT-5 trial compared tirzepatide (the active ingredient in Zepbound) and semaglutide directly